Tenderwize
Wróć do wyszukiwania

Open-house biologics rebate agreement for Triptorelin embonate

Techniker Krankenkasse·Hamburg, Germany·Deadline Sep 29, 2027 · 400 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-22 - Triptorelin embonat

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Participation is limited to pharmaceutical entrepreneurs meeting AMG seat and authorisation requirements for the releva...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Conclusion of pharmaceutical rebate agreements under Section 130a(8) SGB V for the active substance Triptorelin embonate.
  • Open-house model with uniform terms for all suitable pharmaceutical companies; no individual contract negotiations.
Pokaż pełne podsumowanie

Open-house pharmaceutical supply arrangement in Germany for Triptorelin embonate (CPV 33600000) led by Techniker Krankenkasse with hkk and HEK as participating buyers. The procedure is non-exclusive, with no individual negotiations and open accession possible throughout the contract period. The contract term runs from 01.10.2025 to 30.09.2027 at the latest, with automatic earlier end if patent/market exclusivity expires. No contract value is stated. Procurement documents are available via the portal, but only the notice/XML text was analyzed, not the full documents.

Ryzyka

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Participation is limited to pharmaceutical entrepreneurs meeting AMG seat and authorisation requirements for the releva...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the relevant medicinal product.
  • Applicant must have its registered seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-house biologics rebate agreement for Triptorelin embonate

Open-house agreement for pharmaceutical rebate contracts concerning the active substance Triptorelin embonate. Scope is nationwide in Germany and the arrangement is non-exclusive, with uniform conditions and no individual negotiations. The lot information comes from structured data and the XML notice.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Sep 2025 - Sep 2027

Kategoria

Pharmaceutical products

Termin

Deadline Sep 29, 2027

Szczegóły zamówienia

Data publikacji
07 Aug 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
521224-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3